Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Electromed ( (ELMD) ) has shared an announcement.
Electromed, Inc. reported record financial results for the fourth quarter and full fiscal year 2025, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth. The company achieved a 17.3% increase in net revenue for Q4 FY 2025, reaching $17.4 million, and a 30.2% rise in operating income to $3.0 million. For the full fiscal year, net revenue grew by 17.0% to $64.0 million, with operating income increasing by 46.8% to $9.7 million. Electromed’s strategic initiatives, including expanding its direct sales team and optimizing manufacturing, contributed to these results, reinforcing its position in the airway clearance space.
The most recent analyst rating on (ELMD) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Electromed stock, see the ELMD Stock Forecast page.
Spark’s Take on ELMD Stock
According to Spark, TipRanks’ AI Analyst, ELMD is a Outperform.
Electromed’s strong financial performance and positive earnings call outlook are somewhat offset by bearish technical signals and a moderate valuation. The company’s consistent revenue growth and profitability are significant strengths, but technical analysis indicates potential short-term challenges.
To see Spark’s full report on ELMD stock, click here.
More about Electromed
Electromed, Inc. is a company that manufactures, markets, and sells airway clearance therapy products, including the SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function. Headquartered in New Prague, Minnesota, Electromed was founded in 1992.
Average Trading Volume: 73,558
Technical Sentiment Signal: Buy
Current Market Cap: $169.4M
Find detailed analytics on ELMD stock on TipRanks’ Stock Analysis page.